Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 478 participants.
Also called NCT06339086
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 478 participants
- Sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd.
- Registry
-
NCT06339086
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT06339086. Randomized; no masking; primary purpose treatment. Start 2024-04 (anticipated); primary completion 2025-08-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Semaglutide Injection
- Intervention (Drug)
- Semaglutide Injection(Ozempic®)
- Intervention (Drug)
- Metformin
- Lead sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct06339086- Content hash
737e7e3d2c5ea8b396087c7e81172659cdf6405541c44c1a3502fbeae28a28b6